Background. We assessed factors associated with antiretroviral therapy (ART) adherence, including specific ART medications.
Combination antiretroviral therapy (ART) has led to an unprecedented reduction in human immunodeficiency virus (HIV)-associated morbidity and mortality [1] [2] [3] [4] [5] [6] . ART adherence is influenced by a number of factors, including regimen complexity and drug toxicity [3] , sociodemographic and socioeconomic factors [1] , and psychosocial characteristics [1, 3, 7] . Suboptimal ART adherence has been associated with black race [7] [8] [9] [10] , injection drug use (IDU) [7, 8] , smoking [11, 12] , earlier calendar year of the study [1] , previous HIV plasma load rebound [1] , regimens including a protease inhibitor (PI) [4, 7] , greater pill burden [13] [14] [15] [16] , higher dose frequency [14, 16, 17] , occurrence of symptoms [18, 19] , and negative attitudes toward treatment [20, 21] . Factors found to be associated with better ART adherence are older age [1, 7, 22] and history of opportunistic infection [9] .
To date, most analyses have been too small to assess the relationship between ART adherence and specific medications. Studies involving class-specific analyses have found an association between higher adherence and nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimens as compared to PI-based regimens [23, 24] . Findings from 2 meta-analyses [25, 26] suggest that geographic region of residence may play a role, with adherence in developing regions being superior to adherence in developed regions. To date, we are unaware of a single ART study large enough and geographically diverse enough to directly compare adherence by geographic region, particularly across Europe and North America.
In this article, we aim to describe the consistency of ART adherence and assess factors associated with ART adherence on the basis of data collected from participants of the Strategies for Management of Antiretroviral Therapy (SMART) study. Data from the SMART study were collected in 33 countries on 6 continents and, to our knowledge, compose the largest set of prospectively collected data on ART adherence. This allows for unique contributions to the current adherence literature, including by-drug analysis and by-region-of-residence analysis.
METHODS

Data
The SMART study was a multicenter, randomized trial designed to compare the long-term clinical consequences of 2 strategies of antiretroviral management: drug conservation (DC) versus viral suppression (VS). DC strategy participants received interrupted ART while maintaining a CD4 + T-cell count of ≥250 cells/mm 3 . VS strategy participants received continuous ART. Enrollment began in January 2002, and 5472 participants were enrolled. In January 2006, the trial was terminated early after interim analyses revealed that participants in the DC group had over twice the risk of death or disease progression than participants in the VS group [2] . The DC versus VS comparison is not the focus of this article.
Participants were seen 1, 2, 4, 6, 8, 10, and 12 months following randomization and every 4 months thereafter. Total follow-up time was approximately 3700 person-years in each group, with a mean follow-up time of 16 months [2] . Baseline participant demographic information (such as age, race, sex, region of residence, mode of transmission, and level of education) and history of AIDS-defining illnesses were collected at randomization; data on ART regimen, CD4 + T-cell count, HIV plasma load, and event status were collected at every visit; and data on smoking behavior and prescription of concomitant drugs were updated annually. Adherence measurements were collected at baseline and every 4 months thereafter for participants receiving ART at the time of the visit, using the Community Programs for Clinical Research on AIDS Antiretroviral Medication Adherence Self-Report Form (form 065 [27] ). Participants were asked to rate their adherence to each and every drug in their regimen by reporting whether, during the previous 7 days, they had taken "all," "most," "about one-half," "very few," or "none" of their pills for each drug prescribed.
The design and data collection methods of the SMART study are published in detail elsewhere [2] .
Statistical Methods
Participants were dichotomized into high and suboptimal adherence groups on the basis of whether, at a given visit, they reported taking "all" pills for each and every drug in their regimen, at a given visit. Participants who reported taking "most," "about half," "very few," or "none" of their pills for any drug in their regimens were classified as having suboptimal adherence. We included participants from both trial arms in all analyses if they were receiving ART.
Odds ratios (ORs) and 95% confidence intervals (CIs) for the association between adherence and several covariates were calculated by fitting a multivariable logistic regression model. Since all adherence measurements for all participants were included in the analysis, ORs and CIs were estimated using generalized estimating equations (GEEs) to account for the potential correlation between repeated measurements in the same person. An autoregressive variance-covariance structure was specified to explain the correlation between adherence measurements at different visits for the same person.
Categorical covariates investigated included study arm (DC and VS), sex, mode of transmission (same sex, opposite sex, IDU, and other/unknown), race/ethnicity (Asian, black, Latino, other/mixed, and white), formal level of education received (less than high school, high school/some college/university, and bachelors degree or above), geographic region of residence (Australia and New Zealand, Canada, Eastern Europe, Western Europe, the Far East and Asia, the Middle East and Africa, South America, and the United States), calendar year (2002) (2003) (2004) (2005) (2006) (2007) , current regimen (NRTI only, unboosted PI based, boosted PI based, other, NNRTI based), maximum number of doses per day in the regimen (1 dose, 2 doses, and ≥3 doses), smoking status, prescription of concomitant drugs (medicine for comorbidities, which includes other HIVrelated medicines and medication for other ailments), history of AIDS-defining events at baseline, and occurrence of clinical events during the 12 months prior to a follow-up visit. The covariate created to describe clinical events included renal, liver, cancer, cardiovascular and infection-related events, as well as AIDS-defining events.
Continuous or numerical covariates investigated were age, latest CD4 + T-cell count ( per 100 cells/mm Additionally, we considered the association between participant adherence and specific drugs. Participant adherence measurements were only included in the by-drug analysis if the current regimen consisted of 2 NRTIs plus 1 boosted PI, unboosted PI, or NNRTI, as specified below. A second multivariable logistic regression model was fit to assess the association between adherence and specific drugs. The NRTI pairs (including fixed-drug combinations) considered were abacavir/ XTC (ABC/XTC), stavudine plus XTC (D4T + XTC), didanosine plus XTC (DDI + XTC), tenofovir disoproxil fumarate/ XTC (TDF/XTC), and zidovudine/XTC (ZDV/XTC), where XTC is either emtricitabine (FTC) or lamivudine (3TC). PIs included atazanavir (ATV), atazanavir plus ritonavir (ATV/r), fosamprenavir (FPV), fosamprenavir plus ritonavir (FPV/r), indinavir (IDV), indinavir plus ritonavir (IDV/r), lopinavir plus ritonavir (LPV/r), and nelfinavir (NFV). NNRTIs were nevirapine (NVP) and efavirenz (EFV). The covariates for number of pills and maximum number of doses per day were not included in this model as they were too highly correlated with the individual drugs.
In both analyses, PROC GENMOD was used in SAS to model the probability that a participant was in the suboptimal adherence group. Therefore, an OR of >1 indicates an increased odds of suboptimal adherence, compared with the odds for the reference group.
Analyses were performed using SAS software (version 9.3; SAS Institute, Cary, NC). All tests of significance were 2-sided and used a P value of < .05 as the threshold of statistical significance. We did not perform any formal corrections for multiplicity.
Finally, we assessed the consistency of adherence over consecutive visits. We restricted this analysis to include only participants who had made 5 consecutive visits while receiving ART and had therefore contributed 5 consecutive adherence measurements. In a subset of 12 856 observations, which included only adherence measurements from visits that were part of a run of 5 consecutive visits, we looked at the percentage of observations that were classified as high adherence for each of the 5 visits.
RESULTS
Of 5472 participants in the SMART study, adherence measurements were collected from 5295 (97%). The remaining 177 participants (3%) did not receive ART during the period of the trial. The median number of adherence measurements per participant was 6 (interquartile range, 5-9; maximum, 17). During the trial, 47 721 study visits were made, of which 37 221 were made by participants who were receiving ART at the time of the visit. There were 35 695 adherence measurements collected (and included in the analyses); therefore, 1526 observations (4%) were missing. We did not attempt to perform imputation; thus, missing data were excluded from the analyses. Of the 5472 participants, 249 (5%) were treatment naive at baseline.
Baseline characteristics of participants whose adherence measurements were included in the analyses are presented in Table 1 , and summary statistics for covariates that were changeable between visits for the same participant are in Table 2 . The majority of adherence measurements came from participants who were in the VS group (61%), were male (73%), were white (43%), acquired HIV through a member of the same sex (51%), were high-school graduates with some college/university (57%), were living in the United States (63%), had no history of a baseline AIDS-defining event (73%), were currently receiving a regimen consisting of NRTIs and NNRTIs (42%), had experienced 3 ART classes (53%), had a maximum of 2 doses per day (68%), had a most recent plasma HIV load of ≤400 copies/mL (82%), were nonsmokers (62%), had not recently been prescribed concomitant drugs (56%), and had not experienced a defined clinical event in the 12 months preceding the visit (96% In a sensitivity analysis restricted to include only participants in the VS group, the results were similar. In another sensitivity analysis, which excluded the first 2 visits after a treatment interruption, the effect of being in the DC group was no longer significant. A total of 4055 participants (74%) were included in the bydrug analysis. There were 22 843 adherence measurements included in the analysis (median, 5 measurements/participant; IQR, 3-7 measurements/participant). Baseline characteristics of participants included in this analysis were similar to those included in the analysis described above, and summary statistics for covariates, which were variable between visits, are presented in Table 2 . The majority of the adherence measurements came from participants who were receiving ZDV/3TC (37%) and those receiving EFV (34%). Table 4 shows factors associated with adherence in the bydrug analysis. In multivariable analysis, non-ART factors found to be independently associated with adherence were similar to those in the primary analysis. There was an association between adherence and both the PI/NNRTI (P < .0001) and the NRTI (P = .0046) drugs in the regimen. Receiving ATV (OR, 1.82; 95% CI, 1.45-2.28; P < .0001), ATV/r (OR, 1.29; 95% CI, 1.09-1.53; P < .0001), FPV (OR, 1.80; 95% CI, 1.10-2.95; P < .0001), IDV (OR, 2.48; 95% CI, 1.66-3.70; P < .0001), IDV/r (OR, 1.79; 95% CI, 1.11-2.89; P < .0001), or LPV/r (OR, 1.61; 95% CI, 1.36-1.90; P < .0001) was found to be associated with suboptimal adherence, compared with receiving EFV. Among NRTIs, receiving TDF/FTC (OR, 0.80; 95% CI, .70-.92; P = .0046) was found to be significantly associated with high adherence, compared with receiving ZDV/ 3TC. After adjustment for pill burden, the effect of NRTIs was no longer significant. Figure 1 demonstrates that 43% of the 12 856 observations were not classified as high adherence for all of the 5 visits. therefore, in 43% of the observations, suboptimal adherence occurred at least once in a series of 5 consecutive visits. It can be seen that suboptimal adherence was reported for all 5 visits in 2% of observations.
DISCUSSION
In this analysis, on the basis of data collected from 5472 participants from 6 continents, several factors were found to be associated with antiretroviral adherence. We found older age, higher level of education, prescription of concomitant drugs, study arm, and higher CD4 + T-cell count to be associated with high adherence. Black race, PI regimens, greater pill burden, higher maximum number of doses in the regimen, and being a current smoker were associated with suboptimal adherence. Two additional findings were unique and directly related to the geographic breadth and size of the SMART study. We found that a participant's geographic region of residence was significantly associated with adherence. We also conducted a by-drug analysis in which we found ATV, ATV/r, FPV, IDV, IDV/r, and LPV/r to be associated with a greater probability of suboptimal adherence, compared with EFV, and TDF/FTC to be associated with a decreased probability of suboptimal adherence, compared with ZDV/3TC. The findings of our study confirm and extend the results of several other studies on factors associated with adherence, and they also provide some additional new insights. Overall, we observed high levels of self-reported excellent adherence. However, there was still a substantial degree of suboptimal adherence reported, which is cause for concern. Interestingly, only 2% of all adherence measurements collected involved differential adherence whereby adherence differed by drugs in the regimen. A further important finding was that, although >80% of people were able to report high adherence at any 1 visit, a much lower proportion (56%) reported high adherence consistently over a series of 5 visits (spanning on average 16 months; Figure 1 ). This finding is consistent with findings from other longitudinal studies of adherence [7, 28] .
We found that being in the DC group was associated with a decreased odds of suboptimal adherence. However, in a sensitivity analysis, when we excluded the first 2 adherence measurements after a treatment interruption, being in the DC group was no longer significantly associated with adherence. It seems possible that participants in the VS group experienced adherence fatigue, but we did not find that long-term adherence improved as a result of treatment interruptions in the DC group. Findings from SMART and other treatment interruption studies support that treatment interruption is associated with an increased risk of opportunistic disease, death, and serious non-AIDS events [2, 29, 30] . Our findings suggest, however, that for clients to maintain long-term adherence to therapy, ongoing adherence-supporting measures and reduction of barriers to adherence are critical.
In this analysis, living in certain regions was also found to be significantly associated with better adherence, compared with living in the United States. There are a number of possible explanations for such differences. Study populations may have differed in a number of patient-related factors not routinely collected in SMART that can affect adherence, such as mental health, substance use, and access to social support. Healthcare-related factors that can impact upon adherence and engagement in care include physician experience, differences in treatment policies, policies to promote retention to care, and differences in health care systems [31, 32] , and sites may have differed in ≥1 of these health system-related factors. Finally, it has been suggested that self-report overestimates adherence because participants are inclined to provide socially desirable answers [33] , and it is possible that the effect of region could be partially due to an effect whereby overestimation of adherence is greater in non-US regions. In the absence of data on these potentially confounding factors, it is extremely difficult to ascertain the reasons for the observed regional differences in ART adherence, and further exploration is needed to gain insight into these issues.
We looked at the association between adherence and specific drugs and found that among PI/NNRTI drugs, ATV, ATV/r, FPV, IDV, IDV/r, and LPV/r were associated with suboptimal adherence, compared with EFV. LPV/r and IDV are typically believed to be associated with higher rates of side effects and were prescribed with twice daily dosing during the study period, which may help to explain this finding. Among NRTIs, TDF/FTC was found to be associated with high adherence, compared with ZDV/3TC. This is likely because, during the trial, TDF/FTC was prescribed with once-daily dosing, whereas ZDV/3TC was prescribed with twice-daily dosing. After adjustment for the number of pills per day, TDF/FTC was no longer significantly associated with adherence. These results, together with the association found between suboptimal adherence and regimens containing a PI, must be interpreted with caution. The choice of a participant's regimen may be based on the clinician's belief regarding a participant's anticipated level of adherence [34] and also depends on previous virologic failure and HIV resistance history. Thus, the differences observed in adherence between specific drugs and certain drug classes may be confounded by participant characteristics and might not reflect a true difference.
Higher dose frequency was found to be significantly associated with suboptimal adherence in our study, as reported in other studies [17] . Several studies have reported the positive impact that once-daily regimens have on adherence [13] [14] [15] . These findings suggest that decreasing dose burden is a practical approach to improving adherence to ART. However, oncedaily regimens may not be considered suitable for people who have difficulty maintaining consistent adherence, as there is the risk of development of resistance in these individuals.
The association between smoking and suboptimal adherence could be explained in part by the fact that smokers are likely to be less health conscious in general [35] . Furthermore, this finding could be accounted for by socioeconomic status, which may be a marker for limited access to care in some countries and to health-related information.
The current findings add to a large body of literature on adherence to ART. The main strengths of our study involve the large number of adherence measurements included in the analysis, its longitudinal nature, and the collection of data from 6 continents. Our findings are based on a large data set, which therefore enhances the validity and reliability of our findings. A large number of studies that have investigated adherence to ART have been cross-sectional and relatively short in duration. Adherence is known to be a dynamic behavioral issue that is unlikely to remain constant in many people. This was clearly demonstrated in our analysis, in which the longitudinal nature of the data showed that adherence varies within participants over different time points. The inclusion of data from 33 countries, in which an interesting relationship between adherence and a participant's geographic region of residence was found, allowed for a novel contribution to the adherence literature.
Our findings in this article are subject to at least 4 limitations. The most important limitation is concerned with the measurement of adherence, as self-report was the only method used to collect the adherence data in the SMART study. In the absence of a gold standard [36] , debate continues about the best method to use for the collection of adherence data. In addition, the self-report method has been criticized for its validity [33] , because it is believed that self-report leads to overestimation of adherence.
We observed high levels of self-reported excellent adherence in our study. However, this is consistent with the high proportion of participants with a recent plasma HIV load of ≤400 copies/mL (82%). Furthermore, criticisms of the self-report method have been challenged by the increasing number of published studies that have demonstrated the ability of selfreported adherence to predict virologic outcomes [7, 22, [37] [38] [39] .
The lack of data on reasons for missing pills is another limiting factor of the research. As stated elsewhere [36] , the reasons for suboptimal adherence are as diverse as the population affected by HIV. Elucidation of these reasons could enhance our understanding of the complex issues that people face in the challenge of maintaining life-long adherence to ART. A further limitation of our study relates to the median number of adherence measurements per participant. Although our analyses involved 35 695 adherence measurements, the median number per participant was 6. This is relatively low in comparison with data from several other adherence studies. Last, the results of our study relate to ART adherence in a trial context, which limits the generalizability of the results.
In conclusion, our study found certain demographic, clinical, and regimen factors to be significantly associated with self-reported ART adherence. Our findings contribute to the understanding of the issues surrounding adherence and can therefore help with the development of potential interventions for people at risk for suboptimal adherence. Our findings support the need to offer people once-daily regimens, when possible. In addition, the regional differences in adherence need further exploration in future studies.
Notes
